Professor Ipsita Roy, Professor in Microbial Biotechnology, organised an international symposium on Friday 14 December where she delivered a keynote speech on Drug-Free Antibacterial Technology for Medical Applications.
The conference, which took place on 14 December at The Hauser Forum in Cambridge, was in collaboration with Lucideon Limited and was the final conclusive conference organized held within the HyMedPoly project , a Marie Sklodowska Curie H2020 Project on Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications.
The symposium hosted over ten international eminent speakers in the field of Microbiology including Professor Chris Lowe, University of Cambridge and Professor Jeremy Webb, Lead of the National Biofilm Centre at the University of Southampton.
Talks and discussions included various crucial topics of the microbiological field such as ‘The Art of Commercialising Research’, ‘Stress Analysis, Design and Fabrication of Biostructures: the Role & Impact of Additive Manufacturing’, ‘Clinical Need and Issues Faced by Drug-Free Antibacterial Technology’ and ‘New Anti-Biofilm Strategies from Understanding Biofilm Life Cycle Dynamics ‘among many others.
Professor Ipsita Roy, who co-organised the event, introduced the conference speaking about new concepts of drug-free antibacterial science technology and delivered a talk on Antibacterial natural polymers, a piece of research she carried out with the Applied Biotechnology Research Group at the University of Westminster.
In her talk, Professor Roy explained how bacteria-derived polymers can be used for the development of novel antimicrobial polymers. Within this, she presented various modes of Polyhydroxyalkanoate (PHAs), polyesters produced by microorganisms, production and their conversion to antimicrobial polymers. Further, she described their application in hard and soft tissue engineering, peripheral nerve conduit production, cardiac patch development and wound healing patches.
Professor Roy’s research has brought PHAs to the forefront of biomedical research and has the potential to bring state of art PHA-based medical devices, tissue/organ replacements and controlled delivery of drugs in to the clinical world within the near future.
Speaking about the conference, Professor Roy said: “It was an excellent conference with leading speakers who delivered state of art talks informing the audience about various aspects of antimicrobial polymers, their manufacture and commercialization. It was particularly an honour to have Professor Chris Lowe to deliver the first Plenary Talk.”